Acute biliary pancreatitis: focus on recurrence rate and costs when current guidelines are not complied. (4th March 2017)

• Record Type: Journal Article
• Authors: Ragnarsson, Tim; Andersson, Roland; Ansari, Daniel; Persson, Ulf; Andersson, Bodil
• Is Part Of: Scandinavian journal of gastroenterology. Volume 52:Number 3(2017)
• Page Start: 264
• Page End: 269
• Publication Date: 2017-03-04
• Subjects: Acute biliary pancreatitis -- costs -- loss of production -- recurrence; Gastroenterology -- Periodicals; Digestive organs -- Diseases -- Periodicals; 616.33
• DOI: 10.1080/00365521.2016.1243258
• Languages: English
• ISSNs: 0036-5521

Abstract

Abstract: Background: International guidelines recommend cholecystectomy within 2–4 weeks after mild to moderate acute biliary pancreatitis (ABP) to prevent recurrence. We aimed to investigate the compliance to guidelines concerning early cholecystectomy and the associated costs. Methods: Admissions for ABP 2011–2013 were retrospectively reviewed. Classification was made according to the revised Atlanta classification. Treatment, time to surgery and recurrence, as well as cost analysis for both in-hospital costs and loss of production (LOP) were performed. Results: In total, 254 patients were included. Some 202 of the ABP patients (80%) underwent definitive treatment during their first attack of ABP (68% cholecystectomy, 17% endoscopic retrograde cholangiopancreatography (ERCP), 15% both interventions) and 186 (73%) were treated within 1 month of discharge. Patients with ERCP alone were significantly older than cholecystectomy cases ( p < .001), but no significant difference was observed between those who underwent ERCP or no treatment ( p = .071). Mild ABP had intervention earlier ( p < .001). In all, 52 patients (20%) had no intervention, out of which 15 were readmitted due to pancreatitis, compared to 3 patients of those treated at the initial admission ( p < .001). The mean cost for hospital care and LOP in mild ABP was €6882 ± 3010 and €9580 ± 7047 for moderate ABP ( p = .001). The cost for a recurrent episode was €16, 412 ± 22, 367. Conclusion: By improved compliance to current guidelines concerning the management of ABP, recurrence rate and associated costs can potentially be reduced.